These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 12843000)

  • 21. Randomized, placebo-controlled, double-blind study of a cytomegalovirus-specific monoclonal antibody (MSL-109) for prevention of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation.
    Boeckh M; Bowden RA; Storer B; Chao NJ; Spielberger R; Tierney DK; Gallez-Hawkins G; Cunningham T; Blume KG; Levitt D; Zaia JA
    Biol Blood Marrow Transplant; 2001; 7(6):343-51. PubMed ID: 11464977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation.
    Foster AE; Gottlieb DJ; Sartor M; Hertzberg MS; Bradstock KF
    Biol Blood Marrow Transplant; 2002; 8(9):501-11. PubMed ID: 12374455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation.
    Borchers S; Bremm M; Lehrnbecher T; Dammann E; Pabst B; Wölk B; Esser R; Yildiz M; Eder M; Stadler M; Bader P; Martin H; Jarisch A; Schneider G; Klingebiel T; Ganser A; Weissinger EM; Koehl U
    PLoS One; 2012; 7(12):e50248. PubMed ID: 23272059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Factors associated with cytomegalovirus infection in children undergoing allogeneic hematopoietic stem-cell transplantation.
    Jaing TH; Chang TY; Chen SH; Wen YC; Yu TJ; Lee CF; Yang CP; Tsay PK
    Medicine (Baltimore); 2019 Jan; 98(4):e14172. PubMed ID: 30681583
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of Cytomegalovirus Viremia after Allogeneic Stem Cell Transplantation: A Review on CMV-Specific T Cell Reconstitution.
    van der Heiden P; Marijt E; Falkenburg F; Jedema I
    Biol Blood Marrow Transplant; 2018 Sep; 24(9):1776-1782. PubMed ID: 29626514
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
    Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
    Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Different kinetics in anti-cytomegalovirus immunity reconstitution evaluated by lymphocyte proliferation and IFN-gamma production in allogeneic and autologous bone marrow transplantation.
    Mendes AV; Benard G; Pereira CB; Kallas EG; Duarte AJ; Pannuti CS; Dulley FL; Machado CM
    Acta Haematol; 2002; 107(4):187-94. PubMed ID: 12053145
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible Impact of Cytomegalovirus-Specific CD8
    Ogonek J; Varanasi P; Luther S; Schweier P; Kühnau W; Göhring G; Dammann E; Stadler M; Ganser A; Borchers S; Koehl U; Weissinger EM; Hambach L
    Biol Blood Marrow Transplant; 2017 Jul; 23(7):1046-1053. PubMed ID: 28344058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
    Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
    Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reconstitution of HLA-A*2402-restricted cytomegalovirus-specific T-cells following stem cell transplantation.
    Gondo H; Himeji D; Kamezaki K; Numata A; Tanimoto T; Takase K; Aoki K; Henzan H; Nagafuji K; Miyamoto T; Ishikawa F; Shimoda K; Inaba S; Tsukamoto H; Horiuchi T; Nakashima H; Otsuka T; Kato K; Kuroiwa M; Higuchi M; Shibuya T; Kamimura T; Kuzushima K; Tsurumi T; Kanda Y; Harada M
    Int J Hematol; 2004 Dec; 80(5):441-8. PubMed ID: 15646657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictors for persistent cytomegalovirus reactivation after T-cell-depleted allogeneic hematopoietic stem cell transplantation.
    Almyroudis NG; Jakubowski A; Jaffe D; Sepkowitz K; Pamer E; O'Reilly RJ; Papanicolaou GA
    Transpl Infect Dis; 2007 Dec; 9(4):286-94. PubMed ID: 17511819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation.
    Pastore D; Delia M; Mestice A; Perrone T; Carluccio P; Gaudio F; Giordano A; Rossi AR; Ricco A; Leo M; Liso V; Specchia G
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):550-7. PubMed ID: 20457268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-CMV-IgG positivity of donors is beneficial for alloHSCT recipients with respect to the better short-term immunological recovery and high level of CD4+CD25high lymphocytes.
    Jaskula E; Dlubek D; Tarnowska A; Lange J; Mordak-Domagala M; Suchnicki K; Sedzimirska M; Borowik A; Mizia S; Lange A
    Viruses; 2015 Mar; 7(3):1391-408. PubMed ID: 25807050
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus pp65 antigenemia-guided pre-emptive treatment with ganciclovir after allogeneic stem transplantation: a single-center experience.
    Manteiga R; Martino R; Sureda A; Labeaga R; Brunet S; Sierra J; Rabella N
    Bone Marrow Transplant; 1998 Nov; 22(9):899-904. PubMed ID: 9827819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.
    Meijer E; Boland GJ; Verdonck LF
    Clin Microbiol Rev; 2003 Oct; 16(4):647-57. PubMed ID: 14557291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Leukemia.
    Inagaki J; Noguchi M; Kurauchi K; Tanioka S; Fukano R; Okamura J
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):300-306. PubMed ID: 26371373
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytomegalovirus detection in blood and bronchoalveolar lavage, and prophylaxis or preemptive treatment with ganciclovir in children with allogeneic stem cell transplantation].
    Figueroa C; Bonduel M; Paganini H; Botto H; Casimir L
    Enferm Infecc Microbiol Clin; 2006 Mar; 24(3):162-6. PubMed ID: 16606557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.